Congress is facing pressure to improve the regulatory process for biogeneric drugs, but researchers say policies likely won't be implemented before 2011. Consumer and medical student groups that are fighting for a "real" regulatory pathway for biogenerics say currently proposed health reform bills might prevent production of most biogenerics but argue that allowing approval of these drugs could save $71 billion in 10 years.

Full Story:
PharmaTimes (U.K.)

Related Summaries